WHO updates essential medicines list, adding cancer, diabetes, cystic fibrosis, and haemophilia treatments to expand global access to priority care
WHO updates essential medicines list, adding new treatments for cancer, diabetes with comorbidities, and several chronic health conditions in its latest revision.
Also read: WHO pledges support for Lagos healthcare reforms
The World Health Organisation announced the updates on Friday, marking the 24th edition of the Essential Medicines List (EML) and the 10th edition of the Essential Medicines for Children (EMLc).
Among the additions are medicines for cystic fibrosis, psoriasis, haemophilia, and blood-related disorders, alongside new cancer therapies that meet strict survival benefit criteria.
“The new editions of essential medicines lists mark a significant step toward expanding access to new medicines with proven clinical benefits,” said Dr Yukiko Nakatani of WHO.
Launched in 1977, the WHO EML has become a trusted global policy tool adopted by more than 150 countries to guide procurement, supply, and health insurance reimbursement.
This year, the WHO Expert Committee reviewed 59 applications, approving 20 new medicines for adults and 15 for children, as well as new use indications for seven existing medicines.
The updated lists now feature 523 essential medicines for adults and 374 for children.
Cancer, the world’s second-leading cause of death, claims nearly 10 million lives annually. With rigorous review standards, only therapies proven to extend life by at least four to six months are included on the list.
Also read: World Asthma Day: LASUTH advocates for increased asthma awareness, affordable inhaler access
The revisions underscore WHO’s push to make priority treatments more accessible worldwide, especially in low- and middle-income countries.
